A leading Indian manufacturer of reproductive healthcare products and personal wellness solutions, renowned for its diverse portfolio since 1993, has garnered attention in the stock market. Despite a minor dip in share price, the company has demonstrated remarkable growth with a 22.2% surge in quarterly profits, signalling strong market performance and operational efficiency.
Share Price Movement
The share price of Cupid Limited went down 4.5 percent to Rs. 66.05 per share on Monday, a decline from its previous close of Rs. 69.16 per share. The market capitalisation now stands at approximately Rs. 1,003.65 crore as of February 17, 2025.
Business Outlook
In March 2024, the company acquired land in Palava, Maharashtra, to expand its production capacity by 1.5 times. This will increase annual output by about 770 million male condoms and 75 million female condoms.
CUPID is a global leader, being the first to receive WHO/UNFPA pre-qualification for both male and female condoms. With exports to over 105 countries, international markets contribute more than 90 percent of its revenue.
Q3 Financial Highlights
In Q3FY25, revenue stood at Rs. 51 crore, reflecting a 27.5 percent YoY growth from Rs. 40 crore in Q3FY24 and an 8.5 percent QoQ increase from Rs. 47 crore in Q2FY25. Profit for Q3FY25 came in at Rs. 11 crore, marking a 22.2 percent YoY rise from Rs. 9 crore in Q3FY24 and a 10 percent QoQ improvement from Rs. 10 crore in Q2FY25.
Competitors
Cupid’s competitors include Colgate-Palmolive, Hindustan Unilever (HUL), Godrej Consumer, Dabur India Ltd., and Procter & Gamble Hygiene, all of which operate in the personal care and consumer goods sector. These companies compete in product categories like healthcare, hygiene, and wellness.
Cupid is currently trading at a P/E of 19.24, which is below the industry P/E of 34.07.
Written By Fazal Ul Vahab C H
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
